Abstract
There is ongoing debate on the safety of renin-angiotensin system (RAS) inhibitors in COVID-19. Recently published studies highlight a potential relationship between cardiovascular disease (CVD) and COVID-19. This article aims to summarize the evidence on the use of RAS inhibitors in CVD patients with COVID-19, focusing on safety issues of the RAS inhibitors and their relationship with COVID-19.
MeSH terms
-
Angiotensin II Type 1 Receptor Blockers / pharmacology*
-
Angiotensin-Converting Enzyme Inhibitors / pharmacology*
-
Antihypertensive Agents / pharmacology
-
Betacoronavirus* / drug effects
-
Betacoronavirus* / physiology
-
COVID-19
-
Cardiovascular Diseases* / drug therapy
-
Cardiovascular Diseases* / epidemiology
-
Cardiovascular Diseases* / metabolism
-
Comorbidity
-
Confounding Factors, Epidemiologic
-
Coronavirus Infections / diagnosis
-
Coronavirus Infections / epidemiology
-
Coronavirus Infections / metabolism
-
Global Health
-
Humans
-
Pandemics*
-
Pneumonia, Viral / diagnosis
-
Pneumonia, Viral / epidemiology
-
Pneumonia, Viral / metabolism
-
Renin-Angiotensin System / drug effects*
-
Risk Assessment
-
SARS-CoV-2
-
Severity of Illness Index
Substances
-
Angiotensin II Type 1 Receptor Blockers
-
Angiotensin-Converting Enzyme Inhibitors
-
Antihypertensive Agents